Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1115
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:1115 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:1115 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:1115 | rdfs:label | Ketorolac Tromethamine (Injection, Solution) | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:descripti... | Ketorolac tromethamine is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs). The chemical name for ketorolac tromethamine is (��)-5-benzoyl-2, 3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol, and the structural formula is: Ketorolac tromethamine is a racemic mixture of [-]S and [+]R ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. Ketorolac tromethamine has a pKa of 3.5 and an n-octanol/water partition coefficient of 0.26. The molecular weight of ketorolac tromethamine is 376.41 and the molecular formula is CHNO. Ketorolac tromethamine is available for intravenous (IV) or intramuscular (IM) administration as: 15 mg in 1 mL (1.5%), 30 mg in 1 mL (3%) in sterile solutions; 60 mg in 2 mL (3%) of ketorolac tromethamine in sterile solution is available for IM administration only. The solutions contain 10% (w/v) alcohol, and 6.68 mg, 4.35 mg, and 8.70 mg, respectively, of sodium chloride in sterile water. The pH is adjusted with sodium hydroxide and/or hydrochloric acid, and the solutions are packaged with nitrogen. The sterile solutions are clear and slightly yellow in color. | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:clinicalP... | PHARMACODYNAMICS Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. Ketorolac tromethamine inhibits synthesis of prostaglandins and may be considered a peripherally-acting analgesic. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties. The peak analgesic effect of ketorolac tromethamine occurs within 2 to 3 hours and is not statistically significantly different over the recommended dosage range of ketorolac tromethamine. The greatest difference between large and small doses of ketorolac tromethamine by either route is in the duration of analgesia. PHARMACOKINETICS Ketorolac tromethamine is a racemic mixture of [-]S- and [+]R-enantiomeric forms, with the S-form having analgesic activity. Comparison of IV, IM and Oral Pharmacokinetics The pharmacokinetics of ketorolac tromethamine, following IV, IM and oral doses of ketorolac tromethamine, are compared in Table 1. In adults, the extent of bioavailability following administration of the oral and IM forms of ketorolac tromethamine was equal to that following an IV bolus. Linear Kinetics In adults, following administration of single oral, IM or IV doses of ketorolac tromethamine, in the recommended dosage ranges, the clearance of the racemate does not change. This implies that the pharmacokinetics of ketorolac tromethamine in adults, following single or multiple IM, IV, or recommended oral doses of ketorolac tromethamine, are linear. At the higher recommended doses, there is a proportional increase in the concentrations of free and bound racemate. Distribution The mean apparent volume (V) of ketorolac tromethamine following complete distribution was approximately 13 liters. This parameter was determined from single-dose data. The ketorolac tromethamine racemate has been shown to be highly protein-bound (99%). Nevertheless, even plasma concentrations as high as 10 mcg/mL will only occupy approximately 5% of the albumin binding sites. Thus, the unbound fraction for each enantiomer will be constant over the therapeutic range. A decrease in serum albumin, however, will result in increased free drug concentrations. Ketorolac tromethamine is excreted in human milk (see PRECAUTIONS: Lactation and Nursing). Metabolism Ketorolac tromethamine is largely metabolized in the liver. The metabolic products are hydroxylated and conjugated forms of the parent drug. The products of metabolism, and some unchanged drug, are excreted in the urine. Excretion The principal route of elimination of ketorolac and its metabolites is renal. About 92% of a given dose is found in the urine, approximately 40% as Metabolites and 60% as unchanged ketorolac. Approximately 6% of a dose is excreted in the feces. A single-dose study with 10 mg ketorolac tromethamine (n=9) demonstrated that the S-enantiomer is cleared approximately two times faster than the R-enantiomer, and that the clearance was independent of the route of administration. This means that the ratio of S/R plasma concentrations decreases with time after each dose. There is little or no inversion of the R- to S- form in humans. The clearance of the racemate in normal subjects, elderly individuals, and in hepatically and renally impaired patients, is outlined in Table 2. The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD��0.4) compared with 5 hours (SD��1.7) for the R-enantiomer. In other studies, the half-life for the racemate has been reported to lie within the range of 5 to 6 hours. Accumulation Ketorolac tromethamine administered as an IV bolus every 6 hours for 5 days to healthy subjects (n=13), showed no significant difference in Con Day 1 and Day 5. Trough levels averaged 0.29 mcg/mL (SD��0.13) on Day 1 and 0.55 mcg/mL (SD��0.23) on Day 6. Steady state was approached after the fourth dose. Accumulation of ketorolac tromethamine has not been studied in special populations (geriatric, pediatric, renal failure or hepatic disease patients). Kinetics in Special Populations Geriatric Patients Based on single-dose data only, the half-life of the ketorolac tromethamine racemate increased from 5 to 7 hours in the elderly (65 to 78 years) compared with young healthy volunteers (24 to 35 years) (see Table 2). There was little difference in the Cmax for the two groups (elderly, 2.52 mcg/mL��0.77; young, 2.99 mcg/mL��1.03) (see PRECAUTIONS���Geriatric Use). Pediatric Patients Following a single intravenous bolus dose of 0.5 mg/kg in 10 children 4 to 8 years old, the half-life was 6 hours (range: 3.5 to 10 h), the average clearance was 0.042 L/hr/kg and the Vd was 0.26 L/kg (range: 0.19 to 0.44 L/kg). In a second study, following a single intravenous dose of 0.6 mg/kg in 24 children 3 to 18 years old, Cwas 4.3��1.7 mcg/mL, Twas 10.25��1.15 minutes, half-life was 3.8��2.6 hours, Cl was 0.0678 L/hr/kg and Vd was 0.25 L/kg. The volume of distribution and clearance of ketorolac in pediatric patients was twice that observed in adult subjects (see Tables 1 and 2). There are no pharmacokinetic data available for ketorolac tromethamine administration by the IM route in pediatric patients. Renal Insufficiency Based on single-dose data only, the mean half-life of ketorolac tromethamine in renally impaired patients is between 6 and 19 hours and is dependent on the extent of the impairment. There is poor correlation between creatinine clearance and total ketorolac tromethamine clearance in the elderly and populations with renal impairment (r=0.5). In patients with renal disease, the AUC���of each enantiomer increased by approximately 100% compared with healthy volunteers. The volume of distribution doubles for the S-enantiomer and increases by 1/5th for the R-enantiomer. The increase in volume of distribution of ketorolac tromethamine implies an increase in unbound fraction. The AUC���ratio of the ketorolac tromethamine enantiomers in healthy subjects and patients remained similar, indicating there was no selective excretion of either enantiomer in patients compared to healthy subjects (see WARNINGS���Renal Effects and Table 2). Hepatic Insufficiency There was no significant difference in estimates of half-life, AUC���and Cin 7 patients with liver disease compared to healthy volunteers (see PRECAUTIONS���Hepatic Effects and Table 2). Race Pharmacokinetic differences due to race have not been identified. | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:activeIng... | dailymed-ingredient:Ketorol... | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:contraind... | (see also Boxed WARNING) | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:supply | Ketorolac Tromethamine Injection, USP for intramuscular and intravenous use is available in a Carpuject' sterile cartridge unit: 15 mg: 15 mg/mL, 1 mL Carpuject' sterile cartridge unit (with Luer Lock) box of 10, List 2288. 30 mg: 30 mg/mL, 1 mL Carpuject' sterile cartridge unit (with Luer Lock) box of 10, List 2287. Ketorolac Tromethamine Injection, USP for intramuscular use only is available in a Carpuject' sterile cartridge unit: 60 mg: 30 mg/mL, 2 mL Carpuject' sterile cartridge unit (with Luer Lock) box of 10, List 2287. Ketorolac Tromethamine Injection, USP for intramuscular and intravenous use is available as: 15 mg: 15 mg/mL, 1 mL Vial box of 25, List 3793. 30 mg: 30 mg/mL, 1 mL Vial box of 25, List 3795. Ketorolac Tromethamine Injection, USP for intramuscular use only is available as: 60 mg: 30 mg/mL, 2 mL Vial box of 25, List 3796. Store at 20 to 25��C (68 to 77��F). [See USP Controlled Room Temperature.] Retain in carton until time of use. PROTECT FROM LIGHT. Carpujects are packaged in SLIM-PAK tamper detection package. HOSPIRA, INC., LAKE FOREST, IL 60045 USA | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:boxedWarn... | WARNING Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days) management of moderately severe acute pain that requires analgesia at the opioid level. It is NOT indicated for minor or chronic painful conditions. Ketorolac tromethamine is a potent NSAID analgesic, and its administration carries many risks. The resulting NSAID-related adverse events can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately. Increasing the dose of ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will result in increasing the risk of developing serious adverse events. Gastrointestinal Effects Renal Effects Risk of Bleeding Hypersensitivity Intrathecal or Epidural Administration Labor, Delivery and Nursing Concomitant Use with NSAIDs DOSAGE AND ADMINISTRATION Ketorolac Tromethamine Tablets Special Populations | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:activeMoi... | dailymed-ingredient:Ketorol... | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:inactiveI... | dailymed-ingredient:Sodium_... | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:inactiveI... | dailymed-ingredient:Water | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:inactiveI... | dailymed-ingredient:Alcohol | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:inactiveI... | dailymed-ingredient:Hydroch... | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:inactiveI... | dailymed-ingredient:Sodium_... | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:precautio... | GENERAL:<br/>INFORMATION FOR PATIENTS: Ketorolac tromethamine is a potent NSAID and may cause serious side effects such as gastrointestinal bleeding or kidney failure, which may result in hospitalization and even fatal outcome. Physicians, when prescribing ketorolac tromethamine, should inform their patients or their guardians of the potential risks of ketorolac tromethamine treatment (see Boxed WARNING, WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS sections). Advise patients not to give ketorolac tromethamine tablets to other family members and to discard any unused drug. Remember that the total duration of ketorolac tromethamine therapy is not to exceed 5 (five) days in adults or a single dose in pediatric patients ages 2 to 16 years.<br/>DRUG INTERACTIONS: Ketorolac is highly bound to human plasma protein (mean 99.2%). Warfarin, Digoxin, Salicylate and Heparin The in vitro binding of warfarinto plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL. Ketorolac does not alter digoxin protein binding. In vitro studies indicate that, at therapeutic concentrations of salicylate (300 mcg/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential two-fold increase in unbound ketorolac plasma levels. Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam,acetaminophen, phenytoin, and tolbutamide did not alter ketorolac tromethamine protein binding. In a study involving 12 volunteers, ketorolac tromethamine tablets were co-administered with a single dose of 25 mg warfarin, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin. In another study, ketorolac tromethamine injection was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes(3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo. Although these results do not indicate a significant interaction between ketorolac tromethamine and warfarin or heparin, the administration of ketorolac tromethamine to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored (see WARNINGS and PRECAUTIONS). Furosemide Ketorolac tromethamine administered IV or IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%). Probenecid Concomitant administration of ketorolac tromethamine tablets and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately 3-fold from 5.4 to 17.8 mcg/h/mL) and terminal half-life increased approximately 2-fold from 6.6 to 15.1 hours. Therefore, concomitant use of ketorolac tromethamine and probenecid is contraindicated. Lithium Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs. The effect of ketorolac tromethamine on plasma lithium has not been studied, but cases of increased lithium plasma levels during ketorolac tromethamine therapy have been reported. Methotrexate Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate. The effect of ketorolac tromethamine on methotrexate clearance has not been studied. Nondepolarizing Muscle Relaxants In postmarketing experience, there have been reports of a possible interaction between ketorolac tromethamine injection and nondepolarizing muscle relaxants that resulted in apnea. The concurrent use of ketorolac tromethamine with muscle relaxants has not been formally studied. ACE Inhibitors Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients. Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine). Psychoactive Drugs Hallucinations have been reported when ketorolac tromethamine was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam). Morphine Ketorolac tromethamine injection has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions. Do not mix ketorolac tromethamine and morphine in the same syringe. There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs.<br/>Carcinogenesis, Mutagenesis, and Impairment of Fertility: An 18-month study in mice with oral doses of ketorolac tromethamine at 2 mg/kg/day (0.9 times the human systemic exposure at the recommended IM or IV dose of 30 mg qid, based on area-under-the-plasma concentration curve [AUC]), and a 24-month study in rats at 5 mg/kg/day (0.5 times the human AUC), showed no evidence of tumorigenicity. Ketorolac tromethamine was not mutagenic in the Ames test, unscheduled DNA synthesis and repair, and in forward mutation assays. Ketorolac tromethamine did not cause chromosome breakage in the in vivo mouse micronucleus assay. At 1590 mcg/mL and at higher concentrations, ketorolac tromethamine increased the incidence of chromosomal aberrations in Chinese hamster ovarian cells. Impairment of fertility did not occur in male or female rats at oral doses of 9 mg/kg (0.9 times the human AUC) and 16 mg/kg (1.6 times the human AUC) of ketorolac tromethamine, respectively.<br/>Pregnancy: Pregnancy Category C. Reproduction studies have been performed during organogenesis using daily oral doses of ketorolac tromethamine at 3.6 mg/kg (0.37 times the human AUC) in rabbits and at 10 mg/kg (1.0 times the human AUC) in rats. Results of these studies did not reveal evidence of teratogenicity to the fetus. Doses of ketorolac tromethamine tablets at 1.5 mg/kg (0.14 times the human AUC), administered after gestation day 17, caused dystocia and higher pup mortality in rats. There are no adequate and well-controlled studies of ketorolac tromethamine in pregnant women. Ketorolac tromethamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br/>Labor and Delivery: The use of ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage (see CONTRAINDICATIONS).<br/>Lactation and Nursing: After a single administration of a 10 mg ketorolac tromethamine tablet to humans, the maximum milk concentration observed was 7.3 ng/mL and the maximum milk-to-plasma ratio was 0.037. After one day of dosing (qid), the maximum milk concentration was 7.9 ng/mL and the maximum milk-to-plasma ratio was 0.025. Because of the possible adverse effects of prostaglandin-inhibiting drugs on neonates, use in nursing mothers is CONTRAINDICATED.<br/>Pediatric Use: The safety and effectiveness of single doses of ketorolac tromethamine injection have been established in pediatric patients between the ages of 2 and 16 years. Ketorolac tromethamine injection has been shown to be effective in the management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Safety and efficacy in pediatric patients below the age of 2 have not been established. Therefore, ketorolac tromethamine injection is not recommended in pediatric patients below the age of 2. The risk of bleeding was greater in those patients administered ketorolac tromethamine injection following tonsillectomy. Physicians should consider the increased risk of bleeding before deciding to administer ketorolac tromethamine injection in patients following tonsillectomy (see WARNINGS: Hemorrhage and Pediatrics and Tonsillectomy). The risks identified in the adult population with ketorolac tromethamine injection use also apply to pediatric patients. Therefore, consult the CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS sections when prescribing ketorolac tromethamine injection to pediatric patients.<br/>Geriatric Use (���65 Years of Age): Because ketorolac tromethamine may be cleared more slowly by the elderly (see CLINICAL PHARMACOLOGY) who are also more sensitive to the adverse effects of NSAIDs (see WARNINGS���Renal Effects), extra caution and reduced dosages (see DOSAGE AND ADMINISTRATION) must be used when treating the elderly with ketorolac tromethamine injection. The lower end of the ketorolac tromethamine injection dosage range is recommended for patients over 65 years of age and total daily dose is not to exceed 60 mg. The incidence and severity of gastrointestinal complications increases with increasing dose of, and duration of treatment with, ketorolac tromethamine. | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:overdosag... | Symptoms following acute NSAIDs overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose. Patients should be managed by symptomatic and supportive care following a NSAIDs overdose. There are no specific antidotes. Emesis and/or activated charcoal (60 g to 100 g in adults, 1 g/kg to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large oral overdose (5 to 10 times the usual dose). In controlled overdosage, daily doses of 360 mg of ketorolac tromethamine injection given for 5 days (three times the highest recommended dose), caused abdominal pain and peptic ulcers which healed after discontinuation of dosing. Metabolic acidosis has been reported following intentional overdosage. Single overdoses of ketorolac tromethamine have been variously associated with abdominal pain, nausea, vomiting, hyperventilation, peptic ulcers and/or erosive gastritis and renal dysfunction which have resolved after discontinuation of dosing. Dialysis does not significantly clear ketorolac tromethamine from the blood stream. | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:genericMe... | Ketorolac Tromethamine | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:fullName | Ketorolac Tromethamine (Injection, Solution) | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:adverseRe... | Adverse reaction rates increase with higher doses of ketorolac tromethamine. Practitioners should be alert for the severe complications of treatment with ketorolac tromethamine, such as G.I. ulceration, bleeding and perforation, postoperative bleeding, acute renal failure, anaphylactic and anaphylactoid reactions, and liver failure (see Boxed WARNING, WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION). These NSAID-related complications can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately. The Adverse Reactions Listed Below Were Reported In Clinical Trials As Probably Related To KETOROLAC TROMETHAMINE. (Percentage of incidence in parentheses for those events reported in 3% or more patients) Body as a Whole: edema (4%). Cardiovascular: hypertension. Dermatologic: pruritus, rash. Gastrointestinal: nausea (12%), dyspepsia (12%), gastrointestinal pain (13%), diarrhea (7%), constipation, flatulence, gastrointestinal fullness, vomiting, stomatitis. Hemic and Lymphatic: purpura. Nervous System: headache (17%), drowsiness (6%), dizziness (7%), sweating. Injection-site pain was reported by 2% of patients in multi-dose studies. Body as a Whole: weight gain, fever, infections, asthenia. Cardiovascular: palpitation, pallor, syncope. Dermatologic: urticaria. Gastrointestinal: gastritis, rectal bleeding, eructation, anorexia, increased appetite. Hemic and Lymphatic: epistaxis, anemia, eosinophilia. Nervous System: tremors, abnormal dreams, hallucinations, euphoria, extrapyramidal symptoms, vertigo, paresthesia, depression, insomnia, nervousness, excessive thirst, dry mouth, abnormal thinking, inability to concentrate, hyperkinesis, stupor. Respiratory: dyspnea, pulmonary edema, rhinitis, cough. Special Senses: abnormal taste, abnormal vision, blurred vision, tinnitus, hearing loss. Urogenital: hematuria, proteinuria, oliguria, urinary retention, polyuria, increased urinary frequency. The Following Adverse Events Were Reported From Postmarketing Experience. Body as a Whole: hypersensitivity reactions such as anaphylaxis, anaphylactoid reaction, laryngeal edema, tongue edema (see Boxed WARNING, WARNINGS), angioedema, myalgia. Cardiovascular: hypotension and flushing. Dermatologic: Lyell's syndrome, Stevens-Johnson syndrome, exfoliative dermatitis, maculo-papular rash, urticaria. Gastrointestinal: peptic ulceration, G.I. hemorrhage, G.I. perforation (see Boxed WARNING, WARNINGS), melena, acute pancreatitis, hematemesis, esophagitis. Hemic and Lymphatic: postoperative wound hemorrhage rarely requiring blood transfusion (see Boxed WARNING, WARNINGS and PRECAUTIONS), thrombocytopenia, leukopenia. Hepatic: hepatitis, liver failure, cholestatic jaundice. Nervous System: convulsions, psychosis, aseptic meningitis. Respiratory: asthma, bronchospasm. Urogenital: acute renal failure (see Boxed WARNING, WARNINGS), flank pain with or without hematuria and/or azotemia, nephritis, hyponatremia, hyperkalemia, hemolytic uremic syndrome. | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:warning | (see also Boxed WARNING) ���The combined use of ketorolac tromethamine injection and ketorolac tromethamine tablets is not to exceed 5 days in adults. Only single doses of ketorolac tromethamine injection are recommended for use in pediatric patients. The most serious risks associated with ketorolac tromethamine are: In postmarketing experience, postoperative hematomas and other signs of wound bleeding have been reported in association with the perioperative use of ketorolac tromethamine injection. Therefore, perioperative use of ketorolac tromethamine should be avoided and postoperative use be undertaken with caution when hemostasis is critical (see WARNINGS and PRECAUTIONS). Pediatrics and Tonsillectomy: Physicians should consider the increased risk of bleeding before deciding to administer ketorolac tromethamine injection in patients following tonsillectomy. Ketorolac tromethamine injection is not recommended for use in pediatric patients below the age of 2 years. In a retrospective analysis of patients having undergone tonsillectomy with or without adenoidectomy, the risk of bleeding was 10.1% in patients administered ketorolac tromethamine injection compared to 2.2% in those receiving opioids. The postoperative hemorrhage rate in patients 12 years and younger was 6.5% and 3.3% with and without ketorolac tromethamine injection, respectively. In a prospective study of ketorolac tromethamine injection in pediatric patients (ages 3 to 9 years) undergoing tonsillectomy with or without adenoidectomy, the overall incidence of bleeding was similar between the patients receiving ketorolac tromethamine injection and morphine (16.3% versus 17%, respectively). However, during the first 24 hours after surgery, a higher incidence of bleeding was observed in the ketorolac tromethamine injection group (14.3%) versus the morphine group (4.2%). Renal Effects: Ketorolac tromethamine and its metabolites are eliminated primarily by the kidneys, which, in patients with reduced creatinine clearance, will result in diminished clearance of the drug (see CLINICAL PHARMACOLOGY). Therefore, ketorolac tromethamine should be used with caution in patients with impaired renal function (see DOSAGE AND ADMINISTRATION) and such patients should be followed closely. With the use of ketorolac tromethamine, there have been reports of acute renal failure, interstitial nephritis, and nephrotic syndrome. Because patients with underlying renal insufficiency are at increased risk of developing acute renal failure, the risks and benefits should be assessed prior to giving ketorolac tromethamine to these patients. Hence, in patients with moderately elevated serum creatinine, it is recommended that the daily dose of ketorolac tromethamine injection be reduced by half, not to exceed 60 mg/day. Ketorolac tromethamine is CONTRAINDICATED IN PATIENTS WITH SERUM CREATININE CONCENTRATIONS INDICATING ADVANCED RENAL IMPAIRMENT (see CONTRAINDICATIONS). Hypovolemia should be corrected before treatment with ketorolac tromethamine is initiated. | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:indicatio... | Adult Patients: Ketorolac tromethamine is indicated for the short-term (���5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM ketorolac tromethamine, and the oral dosage form is to be used only as continuation treatment, if necessary. Combined use of IV/IM and the oral dosage form is notto exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND ADMINISTRATION, and ADVERSE REACTIONS). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. Pediatric Patients: The safety and effectiveness of single doses of ketorolac tromethamine injection have been established in pediatric patients between the ages of 2 and 16 years. Ketorolac tromethamine as a single injectable dose, has been shown to be effective in the management of moderately severe acute pain that requires analgesia at the opioid level, usually in the postoperative setting. There is limited data available to support the use of multiple doses of ketorolac tromethamine injection in pediatric patients. Safety and effectiveness have not been established in pediatric patients below the age of 2 years. Use of ketorolac tromethamine injection in pediatric patients is supported by evidence from adequate and well-controlled studies of ketorolac tromethamine injection in adults with additional pharmacokinetic, efficacy and safety data on its use in pediatric patients available in the published literature (see CLINICAL PHARMACOLOGY: Clinical Studies, WARNINGS, and PRECAUTIONS). Ketorolac tromethamine injection has been used concomitantly with morphine and meperidine and has shown an opioid-sparing effect. For breakthrough pain, it is recommended to supplement the lower end of the ketorolac tromethamine injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Ketorolac tromethamine and narcotics should not be administered in the same syringe (see DOSAGE AND ADMINISTRATION���PharmaceuticalInformation for Ketorolac Tromethamine Injection). | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:1115 | dailymed-instance:name | Ketorolac Tromethamine | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:1115 | lld:dailymed |